Published in Vaccine Weekly, January 23rd, 2002
The initiation of this trial with NBI-6024 is the first of two studies planned. A second Phase IIb trial is planned to begin during 2002. Successful completion of these two Phase IIb trials may support the marketing of NBI-6024 for type 1 diabetes. Neurocrine will receive an undisclosed milestone payment from Taisho as a result of the initiation of this Phase IIb clinical trial. The two companies entered into a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly